79,80 This discrepancy could be attributed to many challenges in carrying out high-quality RCTs among Arab countries, including inadequate research resources such as limited funding opportunities, an underdeveloped regulatory framework, inadequate research facilities, and a lack of skilled personnel
But the BBB profile is the most concerning on our list
Elevated levels of triglycerides and free fatty acids in circulation are major factors driving lipid accumulation in the liver, leading to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis
doi: 10.1152/ajpgi.00051.2009
No retatrutide is not approved by the MHRA or EMA as of 2025 and cannot be legally prescribed or dispensed in the UK
The clinical investigators specifically noted that "gastrointestinal adverse events were partially mitigated by the use of a lower starting dose." Starting at 1 mg, which is what the Phase 3 TRIUMPH trials use, provides even more tolerability protection